Iterion Therapeutics, founded as a venture-backed clinical-stage biotechnology company, is dedicated to developing novel targeted cancer therapeutics. The company's core mission is to revolutionize healthcare through innovative drug discovery, with a vision to unlock hope for patients battling cancer. Iterion's lead product, Tegavivint, is a first-in-class, small molecule inhibitor targeting Transducin Beta-like Protein 1 (TBL1), a key component in the Wnt/beta-catenin signaling pathway, which plays a critical role in cell proliferation and differentiation. The company's primary market focus is on creating effective treatments for various types of cancer.

Notable affiliated individuals include experienced professionals from the biotech and pharmaceutical industries, contributing to Iterion's robust leadership team. The company has garnered significant venture capital investment, enabling it to advance its clinical trials and research initiatives. Key achievements include progressing Tegavivint through clinical stages and demonstrating its potential efficacy in preclinical studies. Iterion Therapeutics has made a substantial impact by pioneering innovative approaches to cancer treatment, aiming to provide new therapeutic options for patients with limited alternatives.